MarketMoodz
Hims & Hers tumbles 16% on Q1 loss, weak full-year guidance
Hims & Hers Health slumped in premarket trading after reporting a Q1 net loss of $92 million on revenue of $608 million, up 4% year over year. The company also issued full-year guidance that suggests slower margin growth as it pivots away from GLP-1 dependence toward a broader wellness platform. In March, it struck a Wegovy-on-platform deal with Novo Nordisk and said it would stop advertising cheaper compounding GLP-1 versions.
Key Takeaways
- Q1 net loss of $92 million, up from about $50 million a year ago.
- Q1 revenue rose 4% year over year to $608 million; adjusted EBITDA fell to $44 million from $91 million.
- Full-year revenue guidance up to $3 billion; Q2 revenue guidance $680-700 million; full-year adjusted EBITDA guidance up to $350 million (Q2 up to $55 million).
- Wegovy-on-platform deal with Novo Nordisk and plan to halt advertising cheaper compounding GLP-1 versions.
- Stock fell sharply in premarket trading as investors weigh profitability and the pace of the GLP-1 pivot; Citi described the forecast as mixed and highlighted transition risks.
People Involved
- No specific individuals mentioned
Entities Involved
- Hims & Hers Health, Inc. (HIMS)Digital health and telehealth platform pivoting away from GLP-1 dependence
- Novo Nordisk A/S (NVO)Partner in Wegovy-on-platform arrangement
MarketMoodz Analysis
Investors are recalibrating on a GLP-1–driven growth engine transitioning to a broader wellness platform. The Q1 loss and margin compression put a spotlight on profitability as the company ramps marketing spend and manages customer acquisition during the pivot. The Wegovy-on-platform deal could unlock growth, but execution and unit economics will determine the outcome.
Context matters: GLP-1-based growth powered a wave of digital-health players, and several have struggled to translate early revenue into durable profits. Hims & Hers’ revenue rose 4% in Q1, but adjusted EBITDA fell sharply, highlighting the tension between top-line growth and margins during a strategic shift.
What to watch: progress on Wegovy adoption, updates to the stop of cheaper compounding GLP-1 advertising, and whether full-year guidance remains intact amid potential marketing-cost pressures. Citi’s mixed forecast underscores that investors will want concrete execution metrics and cash-burn trends to gauge the pivot’s success.
Source: Original Article